Clario and PathAI Partner to Enhance Efficiency in GI Clinical Trials with AI
核心洞察
Clario (搜索) and PathAI (搜索) have formed a strategic partnership to improve the efficiency of gastrointestinal (GI) clinical trials by integrating anatomical pathology services with advanced video endoscopy assessments.
The collaboration aims to provide an end-to-end solution for CROs and sponsors, streamlining processes from training and logistics to image analysis and data transfers, all under expert medical oversight.
Clario (搜索) will leverage its expertise in GI trials, including advanced imaging solutions and AI-powered reading for ulcerative colitis (搜索), while PathAI (搜索) will offer its network of GI pathologists and AI-driven histological assessments.
Clario (搜索), a technology company that provides clinical trial endpoint technology solutions, has partnered with PathAI (搜索), a company specializing in AI-powered digital pathology, to improve the efficiency of gastrointestinal (GI) clinical trials. The collaboration aims to provide an integrated solution combining anatomical pathology services and advanced video endoscopy assessments, potentially streamlining the clinical trial process for Crohn's disease and ulcerative colitis (搜索).
Integrated Solution for GI Trials
The partnership between Clario (搜索) and PathAI (搜索) seeks to create a single-vendor offering for contract research organizations (CROs) and sponsors involved in GI clinical trials. This end-to-end process will encompass various aspects, including training, logistics, tissue processing, slide digitization, image analysis, and data transfers, all under the supervision of medical and scientific experts. The goal is to simplify workflows for clinical trial sites, enhancing training, reporting, and document management.
Expertise and Technology
Clario (搜索) brings to the partnership its extensive experience in GI trials, having supported over 130 studies using advanced imaging solutions such as endoscopy, MRI, and ultrasound. Their technologies and scientists aid in reducing site burden and improving trial efficiency through AI-powered reading for ulcerative colitis (搜索) (UC) and high-definition video endoscopy support. PathAI (搜索) contributes its network of expert GI pathologists and anatomical pathology services, focusing on streamlining specimen handling and histological assessments. Their AI-powered offerings are designed to enhance UC assessment, reduce variability in histological scoring, and accelerate biomarker discovery.
Potential Impact on IBD Research
According to PathAI (搜索) Biopharma chief business officer and president Matt Grow, this collaboration will offer an integrated approach in histology and endoscopy for assessing therapeutic efficacy, accelerating biomarker discovery, and therapy development in IBD. Marcela Vieira, gastroenterology medical director at Clario (搜索), added that the combination of endoscopy and histopathology promises to unlock new avenues for clinical research.